- Home
- ESPR vs NGS Comparison
ESPR vs NGS Comparison
Compare ESPR & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- NGS
- Stock Information
- Founded
- ESPR 2008
- NGS 1998
- Country
- ESPR United States
- NGS United States
- Employees
- ESPR N/A
- NGS N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- NGS Oilfield Services/Equipment
- Sector
- ESPR Health Care
- NGS Energy
- Exchange
- ESPR Nasdaq
- NGS Nasdaq
- Market Cap
- ESPR 305.0M
- NGS N/A
- IPO Year
- ESPR 2013
- NGS 2002
- Fundamental
- Price
- ESPR $0.89
- NGS $20.11
- Analyst Decision
- ESPR Buy
- NGS Strong Buy
- Analyst Count
- ESPR 7
- NGS 1
- Target Price
- ESPR $5.93
- NGS $32.00
- AVG Volume (30 Days)
- ESPR 5.7M
- NGS 71.1K
- Earning Date
- ESPR 05-06-2025
- NGS 05-12-2025
- Dividend Yield
- ESPR N/A
- NGS N/A
- EPS Growth
- ESPR N/A
- NGS 260.53
- EPS
- ESPR N/A
- NGS 1.37
- Revenue
- ESPR $259,574,000.00
- NGS $156,742,000.00
- Revenue This Year
- ESPR $5.70
- NGS $12.87
- Revenue Next Year
- ESPR N/A
- NGS $15.40
- P/E Ratio
- ESPR N/A
- NGS $14.68
- Revenue Growth
- ESPR 12.99
- NGS 29.36
- 52 Week Low
- ESPR $0.82
- NGS $16.70
- 52 Week High
- ESPR $3.94
- NGS $29.74
- Technical
- Relative Strength Index (RSI)
- ESPR 36.95
- NGS 53.74
- Support Level
- ESPR $0.93
- NGS $17.63
- Resistance Level
- ESPR $1.11
- NGS $19.68
- Average True Range (ATR)
- ESPR 0.10
- NGS 1.00
- MACD
- ESPR 0.02
- NGS 0.28
- Stochastic Oscillator
- ESPR 25.10
- NGS 90.51
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.